hackint0sh/New-Dataset huggingface dataset:
The research team aims to comprehensively assess the structural and functional changes to the gut microbiome brought about by a high fructose diet. Determining the impact of excess fructose on the microbiome will help identify novel means by which fructose contributes to metabolic disease risk. In addition to identifying strategies to improve metabolic health in adults, data from this proposal could help inform targeted approaches to mitigate future disease risk in vulnerable populations that consume high levels of fructose, such as children. conditions: MASLD conditions: Type 2 Diabetes conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study will be a double-blinded (participants and select study personnel), randomized controlled crossover dietary intervention design. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: All participants undergo both treatment arms but will be blinded to the order. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: Fructose name: glucose measure: Liver proton density fat fraction (PDFF) measure: Degree of fibrosis sex: ALL minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: Mount Sinai Morningside city: New York state: New York zip: 10025 country: United States name: Ryan Walker role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06329531 id: 2022-0992 id: NCI-2024-02555 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-22 date: 2025-04-22 date: 2024-03-26 date: 2024-03-28 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To compare the results of the SOCS-OTS to another standardized screening measure that is currently being used by rehabilitation services at MD Anderson Cancer Center and to ensure that the SOCS-OTS correctly identifies those individuals needing OT services in cancer care. conditions: Cancer conditions: Occupational Therapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Ekta Gupta, MD role: CONTACT phone: 713-745-2327 email: egupta@mdanderson.org name: Ekta Gupta, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06329518 id: HHC-2024-0064 briefTitle: Rezafungin PK in Patients on ECMO overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-03-26 date: 2024-03-26 name: Hartford Hospital class: OTHER name: Melinta Therapeutics, LLC briefSummary: Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum echinocandin, Rezafungin, in critically ill patients receiving ECMO conditions: Sepsis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 8 type: ESTIMATED name: Rezafungin measure: Rezafungin Clearance measure: Rezafungin Area Under the Curve (AUC) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hartford Hospital city: Hartford state: Connecticut zip: 06102 country: United States lat: 41.76371 lon: -72.68509 hasResults: False
nctId: NCT06329505 id: 111-085-B briefTitle: Impact of Extracorporeal Membrane Oxygenation Care Strategy Application Development overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: Pei-Hung Liao class: OTHER briefSummary: The objective of this study was to develop an educational training App for ECMO care, and to apply a blended learning approach to improve the knowledge and skills of nurses. conditions: Learning Problem studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: Comparison of knowledge and skills of nurses between groups after the intervention For 6 months. sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: National Taipei university of nursing and health science city: Taipei country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06329492 id: 23-007937 briefTitle: Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis acronym: A2MRP overallStatus: ENROLLING_BY_INVITATION date: 2024-01-09 date: 2024-12-31 date: 2025-12-31 date: 2024-03-26 date: 2024-04-10 name: Mayo Clinic class: OTHER briefSummary: The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA). conditions: Osteoarthritis conditions: OA conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single group cohort of 20 subjects primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) measure: Adverse Events measure: Visual Analog Scale (VAS) for Pain measure: Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Pain interference measure: Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Physical function measure: Knee Injury and Osteoarthritis Outcome Score (KOOS): measure: Procedure Recommendation sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06329479 id: 1926B briefTitle: A Feasibility Trial for Circadian Rest-activity Rhythm Disorders in Cancer (RALI) overallStatus: RECRUITING date: 2023-06-01 date: 2024-06-01 date: 2024-09-01 date: 2024-03-26 date: 2024-03-26 name: University of Dublin, Trinity College class: OTHER briefSummary: Circadian rest-activity rhythm disorders are common in patients with cancer, particularly in advanced disease. A recent international e-Delphi study has outlined recommendations for the assessment and reporting of the disorder and subsequently an observation study is underway assessing a cohort of patients with advanced cancer. Affected patients are eligible to enter a feasibility study assessing a non-pharmacological multi-modal intervention. conditions: Circadian Rhythm Disorders conditions: Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Cognitive behavioural therapy for Insomnia (CBT-I) name: Bright Light Therapy name: Individualised activity plan name: Clincial review measure: Acceptability and usability of a multi-modal non-pharmacological intervention measure: Adherence to interventions measure: Adverse events measure: Completion rates of research assessments measure: Recruitment rate measure: Symptom assessment measure: Quality of Life assessment measure: Daytime Sleepiness measure: Sleep Quality measure: Physical activity assessment measure: Physical activity and sleep assessment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Our Lady's Hospice & Care Services status: RECRUITING city: Dublin zip: D6W RY72 country: Ireland name: Craig Gouldthorpe role: CONTACT phone: +3534986235 email: gouldthc@tcd.ie lat: 53.33306 lon: -6.24889 facility: St James's Hospital status: RECRUITING city: Dublin zip: D6W RY72 country: Ireland name: Craig Gouldthorpe role: CONTACT phone: +3534986235 email: gouldthc@tcd.ie lat: 53.33306 lon: -6.24889 hasResults: False
nctId: NCT06329466 id: 0000-0002-4205-669X briefTitle: The Effect of Emotional Freedom Technique (EFT) on Pain Intensity and Menstruation Symptoms acronym: EFT overallStatus: ACTIVE_NOT_RECRUITING date: 2022-01-28 date: 2024-06-25 date: 2024-07-25 date: 2024-03-26 date: 2024-03-26 name: Gulay Coskun class: OTHER name: Mersin University briefSummary: The most important indicator of the fertility period, which has an important place in a woman's life, is the menstrual cycle, which begins with menarche and continues until menopause. In this natural process that takes place every month physiologically, some women experience significant pain \[1\]. This condition, defined as dysmenorrhea (painful menstruation), is classified in two ways as primary dysmenorrhea (PD) and secondary dysmenorrhea (SD) \[2,3\]. PD is the most common women's health problem, especially in adolescents and young adults (10-20 years of age) \[1,5\].
The main goal of the treatment approach to PD, which negatively affects women's quality of life in many ways, is to relieve the woman by reducing the pain. Emotional Freedom Technique (EFT) is one of the non-pharmacological and integrated treatment methods for women with primary dysmenorrhea. This practice, which is also referred to as EFT stroke/touch in most sources, is based on expressing the problem by touching the energy meridian points of the body, as in acupuncture and acupressure.
Studies investigating the effect of EFT on pain have reported that it is effective in coping with pain \[33-35\]. However, no randomized controlled study was found in the literature search for the application of EFT in high school students with dysmenorrhea. For this reason, it is thought that if EFT is applied in this age period with a high incidence of dysmenorrhea, important findings can be achieved in terms of parameters such as pain intensity and menstrual symptoms, and it will contribute to the literature by shedding light on similar studies. \[36\]. Therefore, in this study, it was aimed to determine the effect of the emotional freedom technique applied to high school students with primary dysmenorrhea on pain severity and menstruation symptoms. conditions: Dysmenorrhea Primary studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 48 type: ACTUAL name: intervention (EFT) group measure: Mcgill Pain Scale measure: Menstruation Symptom Scale measure: VAS pain scale sex: FEMALE minimumAge: 14 Years maximumAge: 17 Years stdAges: CHILD facility: Mersin University city: Yenişehir state: Mersin zip: 33343 country: Turkey lat: 40.26444 lon: 29.65306 hasResults: False
nctId: NCT06329453 id: 2000033081 briefTitle: Intestinal Immunity in Neurologic Disease overallStatus: RECRUITING date: 2022-08-02 date: 2027-08-31 date: 2027-08-31 date: 2024-03-26 date: 2024-03-26 name: Yale University class: OTHER briefSummary: The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases. conditions: Multiple Sclerosis conditions: Parkinson Disease conditions: REM Sleep Behavior Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Colon Tissue Biopsy measure: Characterization of immune cells from the gastrointestinal mucosa measure: Evaluate spatial transcriptomics of intestinal tissue measure: Characterize the microbiome at different anatomic sites within the gastrointestinal tract sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yale MS Clinic status: RECRUITING city: North Haven state: Connecticut zip: 06473 country: United States name: Cynthia Marques role: CONTACT phone: 203-287-6100 email: cynthia.marques@yale.edu name: Dimitri Duvilaire role: CONTACT phone: 2032876100 email: dimitri.duvilaire@yale.edu name: Erin Longbrake, MD role: PRINCIPAL_INVESTIGATOR lat: 41.39093 lon: -72.85954 hasResults: False
nctId: NCT06329440 id: 2023/880 briefTitle: Comparison of Supraclavicular and Costoclavicular Brachial Plexus Blocks in Adult Patients overallStatus: RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2024-10-05 date: 2024-03-26 date: 2024-04-18 name: Istanbul University class: OTHER briefSummary: Hemidiaphragmatic paresis is a common side effect of brachial plexus blocks such as supraclavicular or infraclavicular block techniques. It has been shown that diaphragma thickness is affected at some extent in supraclavicular block and also in costoclavicular block which is accepted as an infraclavicular approach. However, these two approaches have not been extensively investigated before in terms of the diaphragmatic paresis. Here, it is aimed to compare these two methods considering their effects on diaphragma thickness in inspirium and in expirium. Moreover, the performance properties such as motor and sensory block onset, needle visualization time, needle visualization difficulty, postoperative pain scores, and lastly the perfusion index which is known to be reflecting vasodilation will be investigated. conditions: Diaphragm Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Ultrasonographic measurement of diaphragm thickness measure: Diaphragm thickness fraction (centimeters) measure: Diaphragm thickness at the end of expirium (centimeters). measure: Diaphragm thickness at the end of inspirium (centimeters). measure: Perfusion index change measure: Motor and sensory block onset time measure: Postoperative pain scores (0-10) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istanbul University Istanbul Faculty of Medicine status: RECRUITING city: Istanbul country: Turkey name: Meltem Savran Karadeniz, MD, Assoc Prof role: CONTACT email: mskaradeniz@gmail.com name: Ozgur Selek, MD role: CONTACT phone: 00905057883600 lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06329427 id: IRB00098063 briefTitle: Dragon Ambient eXperience (DAX) Copilot Evaluation acronym: DAX overallStatus: COMPLETED date: 2023-06-19 date: 2023-12-15 date: 2023-12-15 date: 2024-03-26 date: 2024-03-29 name: Wake Forest University Health Sciences class: OTHER name: Hieu Nguyen, MS - Biostatician name: McKenzie Isreal, MPH - project manager name: Casey Stephens, MPH - Health services researcher briefSummary: AI solutions like, Dragon Ambient eXperience (DAX) Copilot (Nuance/Microsoft), hold the potential to significantly enhance provider and patient interactions and alleviate pain points that contribute to burn out. Atrium Health was the first healthcare system in the world to pilot Nuance's DAX Copilot intelligence (AI) enabled scribe software, which synthesizes a draft clinic note by "listening" to the conversation between a provider and patient. After 180 days of use by primary care clinicians and advanced practice providers (APPs), along with a control group, the investigators assess provider satisfaction, patient experience, and provider efficiency through qualitative and quantitative methods. conditions: Automated Clinical Documentation studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 238 type: ACTUAL name: Dragon Ambient eXperience (DAX) Copilot measure: Total EHR time measure: Work outside of work measure: Time on encounter note documentation measure: Completed appointment rate measure: Same day closure rate measure: Note length measure: Gross revenue per visit measure: wRVU per visit measure: Provider satisfaction measure: Provider interview measure: Patient satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Atrium Health Navicent city: Macon state: Georgia zip: 31201 country: United States lat: 32.84069 lon: -83.6324 facility: Atrium Health Floyd city: Rome state: Georgia zip: 30165 country: United States lat: 34.25704 lon: -85.16467 facility: Atrium Health city: Charlotte state: North Carolina zip: 28203 country: United States lat: 35.22709 lon: -80.84313 facility: Scotland Health Care System city: Laurinburg state: North Carolina zip: 28352 country: United States lat: 34.77405 lon: -79.46282 facility: Atrium Health Wake Forest Baptist city: Winston-Salem state: North Carolina zip: 27157 country: United States lat: 36.09986 lon: -80.24422 hasResults: False
nctId: NCT06329414 id: 00164631 briefTitle: Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis overallStatus: RECRUITING date: 2024-01-16 date: 2026-01 date: 2026-01 date: 2024-03-25 date: 2024-03-25 name: University of Utah class: OTHER briefSummary: The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment. conditions: Multiple Sclerosis conditions: Major Depressive Disorder conditions: Treatment Resistant Depression studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 12 type: ESTIMATED measure: Feasibility of TMS treatment for MDD, per participant retention rates. measure: Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment. measure: Depression response rates (50% reduction in symptoms) will be measured using MADRS scores before and after treatment. measure: Depression remission rates will be measured using MADRS scores before and after treatment. measure: MS lesion burden on MRI will be compared before and after treatment to determine impact of TMS on white matter disease burden. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Utah Health status: RECRUITING city: Salt Lake City state: Utah zip: 84108 country: United States name: Kathleen Shangraw, MD role: CONTACT phone: 801-583-2500 lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06329401 id: AP01-007 briefTitle: A Study Evaluating the Safety and Efficacy of AP01 in Participants With Progressive Pulmonary Fibrosis (PPF) overallStatus: RECRUITING date: 2024-04-03 date: 2026-04 date: 2026-04 date: 2024-03-25 date: 2024-04-24 name: Avalyn Pharma Inc. class: INDUSTRY name: DevPro Biopharma briefSummary: A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks. conditions: Progressive Pulmonary Fibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: AP01 name: Placebo measure: To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID) measure: To evaluate the effect of AP01 high dose, AP01 low dose compared to placebo on quality of life (QoL) measure: To evaluate the effect of AP01 high dose and AP01 low dose compared to placebo on disease progression (defined as absolute FVC percent predicted decline of ≥10% prior to Week 52) measure: To evaluate the change from baseline in quantitative lung fibrosis score. measure: To evaluate the safety of AP01 high dose and AP01 low dose compared to placebo sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Newport Native MD, Inc. status: RECRUITING city: Newport Beach state: California zip: 92663 country: United States lat: 33.61891 lon: -117.92895 facility: Paradigm Clinical Research - Redding status: NOT_YET_RECRUITING city: Redding state: California zip: 96001 country: United States lat: 40.58654 lon: -122.39168 facility: Clinical Site Partners, LCC status: NOT_YET_RECRUITING city: Leesburg state: Florida zip: 34748 country: United States lat: 28.81082 lon: -81.87786 facility: Renstar Medical Research status: NOT_YET_RECRUITING city: Ocala state: Florida zip: 34470 country: United States lat: 29.1872 lon: -82.14009 facility: Clinical Site Partners status: NOT_YET_RECRUITING city: Winter Park state: Florida zip: 32789 country: United States lat: 28.6 lon: -81.33924 facility: Accellacare status: RECRUITING city: Wilmington state: North Carolina zip: 28401 country: United States lat: 34.22573 lon: -77.94471 facility: Southeastern Research Center status: NOT_YET_RECRUITING city: Winston-Salem state: North Carolina zip: 27103 country: United States lat: 36.09986 lon: -80.24422 facility: Lowcountry Lung and Critical Care status: RECRUITING city: Charleston state: South Carolina zip: 29406 country: United States lat: 32.77657 lon: -79.93092 hasResults: False
nctId: NCT06329388 id: CSD-SFRI-013 briefTitle: Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns overallStatus: COMPLETED date: 2023-01-18 date: 2023-07-07 date: 2023-08-11 date: 2024-03-25 date: 2024-03-26 name: TruHeight Vitamins class: INDUSTRY name: San Francisco Research Institute briefSummary: This single-center, randomized controlled pilot study aims to evaluate the efficacy of TruHeight Growth Protein Shake on improving growth patterns in children aged 4-17 years. Over six months, participants will consume the protein shake daily, five times a week, with outcomes measured in terms of type X collagen concentration in urine, height via a stadiometer, and body composition using an INBODY device. conditions: Growth Disorders conditions: Dietary Exposure conditions: Child Development conditions: Bone Development Abnormal conditions: Body Weight conditions: Child Malnutrition studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial (RCT) with two parallel groups (treatment and control group). primaryPurpose: TREATMENT masking: NONE count: 32 type: ACTUAL name: TruHeight Growth Protein Shake measure: Change in Height measure: Change in Type X Collagen Concentration in Urine measure: Change in Body Composition measure: Incidence of Adverse Events sex: ALL minimumAge: 4 Years maximumAge: 17 Years stdAges: CHILD facility: SF Research Institute city: San Francisco state: California zip: 94127 country: United States lat: 37.77493 lon: -122.41942 hasResults: False
nctId: NCT06329375 id: 72967 briefTitle: Food Insecurity Reduction & Strategy Team acronym: FIRST overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-02-05 date: 2025-02-05 date: 2024-03-25 date: 2024-04-17 name: Stanford University class: OTHER briefSummary: This study seeks to address the multifaceted challenges posed by food disparities and their negative consequences on health outcomes, via a comprehensive community health intervention program. Study objectives include: